Addressing a tangible high unmet medical need with a targeted “cornerstone treatment” of rheumatoid arthritis. The problem: Rheumatoid arthritis (RA) is a chronic debilitating disease with a high unmet medical need. Methotrexate (MTX) is the established cornerstone treatment of RA in all stages of the disease but has equally well-documented debilitating side effects which affects the vast majority of patients and in turn reduce MTX to a clinically viable treatment for a subsegment of RA patients, only. The solution: Targeted-MTX has promise to deliver the well understood clinical benefits of the established “cornerstone” treatment(MTX)for RA without the equally documented debilitating side-effects. The company: We have developed a targeted methotrexate (prodrug) that is designed for targeted release at the site of inflammation where high levels of ROS (reactive oxygen species) are present. MTX delivered as a proprietary molecule directly to the target with a game changing capability to disrupt and revolutionize the present treatment paradigm with a market potential of EUR 3.6 bn in RA in the US, EU and Japan. This is the first targeted prodrug technology for methotrexate (MTX) - addressing a high unmet medical need - a treatment with a higher tolerability and less safety issues - comparable or better efficacy - with potential for patients to stay longer on monotherapy / first line therapy With a program deemed eligible for FDA 505(b)(2) as well as FDA fast track program, we may possibly piggyback on knowledge of MTX for a more abbreviated and less risky drug development program.